Mesoblast Limited, Intrexon Corporation and ZIOPHARM Oncology, Inc. to Target Cancers
Published: Oct 23, 2013
MELBOURNE, Australia, GERMANTOWN, Md. and BOSTON, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB), a world leader in the development of cell-based biologic products, Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, today announced a partnership to develop a new class of cancer therapeutics.
Help employers find you! Check out all the jobs and post your resume.